Case Report: Development of severe inflammatory orbitopathy after immune checkpoint inhibitor initiation
We report a case of thyroid eye disease (TED) reactivation, review the literature, and raise awareness of severe ophthalmopathy and myositis following the initiation of cancer treatment with an immune checkpoint inhibitor (ICI). In this case, after starting nivolumab, a 68-year-old woman with a past...
Saved in:
| Main Authors: | Samantha Madala, Alomi Parikh, Kendra Hong, Michael Burnstine |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-06-01
|
| Series: | Frontiers in Ophthalmology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fopht.2025.1574643/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The neurotoxic effects of immune checkpoint inhibitor therapy for melanoma
by: Lavinia Spain, et al.
Published: (2019-06-01) -
Review of Current First-Line Pharmacotherapy Strategies for Thyroid Eye Disease
by: Julia Ryniecka, et al.
Published: (2025-01-01) -
Therapeutic effect of selective interleukin-2-inducible tyrosine kinase inhibitor in orbital fibroblasts from patients with Graves’ orbitopathy
by: Yeonjung Yoon, et al.
Published: (2024-09-01) -
Teprotumumab in the management of thyroid eye disease mechanistic insights and adverse reactions: a comprehensive review
by: Zhibin Xu, et al.
Published: (2025-05-01) -
Immune checkpoint inhibitor-induced thyroiditis and its potential mechanisms
by: Xueqian Mao, et al.
Published: (2025-06-01)